68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

被引:239
|
作者
Poeppel, Thorsten D. [1 ]
Binse, Ina [1 ]
Petersenn, Stephan [2 ]
Lahner, Harald [2 ]
Schott, Matthias [3 ]
Antoch, Gerald [4 ]
Brandau, Wolfgang [1 ]
Bockisch, Andreas [1 ]
Boy, Christian [1 ]
机构
[1] Univ Essen Gesamthsch, Dept Nucl Med, Essen, Germany
[2] Univ Essen Gesamthsch, Dept Endocrinol, Essen, Germany
[3] Univ Dusseldorf, Dept Endocrinol, D-40225 Dusseldorf, Germany
[4] Univ Dusseldorf, Dept Diagnost & Intervent Radiol, D-40225 Dusseldorf, Germany
关键词
Ga-68-DOTATOC PET/CT; Ga-68-DOTATATE PET/CT; NET; RECEPTOR RADIONUCLIDE THERAPY; SOMATOSTATIN ANALOGS; PEPTIDE; SCINTIGRAPHY; CONTRAST; Y-90-DOTATOC; EXPRESSION; GUIDELINES; SST1-SST5; DOSIMETRY;
D O I
10.2967/jnumed.111.091165
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are Ga-68-DOTATATE and Ga-68-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of Ga-68-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of Ga-68-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs (Ga-68-DOTATATE and Ga-68-DOTATOC) in the same NET patients. Methods: Forty patients with metastatic NETs underwent Ga-68-DOTATOC and Ga-68-DOTATATE PET/CT as part of the work-up before prospective peptide receptor radionuclide therapy. The performance of both imaging methods was analyzed and compared for the detection of individual lesions per patient and for 8 defined body regions. A region was regarded positive if at least 1 lesion was detected in that region. In addition, radiopeptide uptake in terms of the maximal standardized uptake value (SUVmax) was compared for concordant lesions and renal parenchyma. Results: Seventy-eight regions were found positive with Ga-68-DOTATATE versus 79 regions with Ga-68-DOTATOC (not significant). Overall, however, significantly fewer lesions were detected with Ga-68-DOTATATE than with Ga-68-DOTATOC (254 vs. 262, P < 0.05). Mean Ga-68-DOTATATE SUVmax across all lesions was significantly lower than Ga-68-DOTATOC (16.0 +/- 10.8 vs. 20.4 +/- 14.7, P < 0.01). Mean SUVmax for renal parenchyma was not significantly different between Ga-68-DOTATATE and Ga-68-DOTATOC (12.7 +/- 3.0 vs. 13.2 +/- 3.3). Conclusion: Ga-68-DOTATOC and Ga-68-DOTATATE possess a comparable diagnostic accuracy for the detection of NET lesions, with Ga-68-DOTATOC having a potential advantage. The approximately 10-fold higher affinity for the sst2 of Ga-68-DOTATATE does not prove to be clinically relevant. Quite unexpectedly, SUVmax of Ga-68-DOTATOC scans tended to be higher than their Ga-68-DOTATATE counterparts.
引用
收藏
页码:1864 / 1870
页数:7
相关论文
共 50 条
  • [21] Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT
    Sawicki, Lino M.
    Deuschl, Cornelius
    Beiderwellen, Karsten
    Ruhlmann, Verena
    Poeppel, Thorsten D.
    Heusch, Philipp
    Lahner, Harald
    Fuehrer, Dagmar
    Bockisch, Andreas
    Herrmann, Ken
    Forsting, Michael
    Antoch, Gerald
    Umutlu, Lale
    EUROPEAN RADIOLOGY, 2017, 27 (10) : 4091 - 4099
  • [22] Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Wild, Damian
    Bomanji, Jamshed B.
    Benkert, Pascal
    Maecke, Helmut
    Ell, Peter J.
    Reubi, Jean Claude
    Caplin, Martyn E.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) : 364 - 372
  • [23] The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
    Sotiropoulos, G.
    Li, J.
    Al-Nahhas, A.
    Spalding, D.
    Tedeschi, M.
    Carroll, R. W.
    Bockisch, A.
    NEUROENDOCRINOLOGY, 2011, 94 : 45 - 45
  • [24] A Study of Radiomic Features Robustness for 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors
    Liberini, V.
    Gallio, E.
    Rampado, O.
    De Santi, B.
    Dionisi, B.
    Ceci, F.
    Pilati, E.
    Finessi, M.
    Bello, M.
    Bisi, G.
    Molinari, F.
    Deandreis, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S252 - S253
  • [25] 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential
    Gravel, Guillaume
    Gimenez-Roqueplo, Anne-Paule
    Halimi, Philippe
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) : 184 - 185
  • [26] 68Ga-DOTATATE PET/CT in Gastroenteropancreatic Neuroendocrine Tumors (NETs): Pearls and Pitfalls
    Metser, Ur
    Murad, Vanessa
    Ortega, Claudia
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [27] 68Ga-DOTATATE PET/MRI for Neuroendocrine Tumors A Pictorial Review
    Nguyen, Nghi C.
    Moon, Chan-Hong
    Muthukrishnan, Ashok
    Furlan, Alessandro
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : E406 - E410
  • [28] Role of 68Ga-DOTATATE PET/CT in evaluation of patients with lung neuroendocrine tumors
    Kunikowska, J.
    Matyskiel, R.
    Zemczak, A.
    Pawlak, D.
    Krolicki, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S188 - S188
  • [29] 68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
    Graham, Michael M.
    Gu, Xiaomei
    Ginader, Timothy
    Breheny, Patrick
    Sunderland, John J.
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (09) : 1452 - 1458
  • [30] PET/CT imaging of neuroendocrine tumors with the use of radiolabeled peptide analogues: the role of 68Ga-DOTATATE
    Vangu, M.
    Mkhize, N.
    Louw, L.
    Purbhoo, K.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56